Gensel Bribery Case: Court Ruling Details and Conviction Process
Key Details of Gensel Bribery Conviction
Gensel founder Kang Se-chan was sentenced to four years in prison on appeal for allegedly attempting to secure new drug clinical trial approval through bribery via Kim Seung-won. The court clearly acknowledged the quid pro quo nature and embezzlement/bribery acts, as confirmed by multiple media reports and the verdict document.
While the first instance court handed down a suspended sentence, the second instance court overturned this to impose a four-year prison term. Kim Seung-won was deemed to have cooperated with Kang despite knowing that new drug development would yield substantial financial benefits. The founder was placed in custody following the ruling. Investigation reports also raised the possibility that Kang had exaggerated clinical results to deceive Kim.
Clarity of Bribery Path and Court Verdict
Gensel founder Kang Se-chan was sentenced to four years in prison on appeal for allegedly attempting to secure new drug clinical trial approval through bribery via Kim Seung-won. The court determined that the bribery path was clear and explicitly acknowledged the quid pro quo nature and embezzlement/bribery acts.
The first instance court had imposed a suspended sentence, but the second instance court overturned this to impose a four-year prison term. The court clearly recognized the quid pro quo nature of the bribery and embezzlement, leading to the conviction.
Kim Seung-won was judged to have cooperated with Kang despite being aware that new drug development could bring significant financial gains. This was cited as a key factor in understanding the case's background and motivation.

Shift from First Instance to Second Instance: Background of Conviction
The Gensel founder Kang Se-chan's case saw a suspended sentence at first instance but was overturned to a four-year prison term on appeal. This is attributed to the court more clearly acknowledging the quid pro quo nature and embezzlement acts.
While the first instance court deemed evidence regarding specific circumstances insufficient for a suspended sentence, the second instance court reviewed additional documents and evidence, confirming that the bribery was clear. In particular, the financial gains Kim Seung-won received during his cooperation with Kang significantly influenced the verdict.
The investigation reports also suggested the possibility that Kang had exaggerated clinical results to deceive Kim. This adds complexity to the case by requiring further analysis of the bribery's background and motivation.
Gensel Founder's Charges and Custody
Gensel founder Kang Se-chan was sentenced to four years in prison on appeal for alleged bribery related to new drug clinical trial approval, resulting in his custody. This represents the final court ruling without further appeals, meaning he will serve the sentence.
Kim Seung-won was found to have cooperated with Kang despite knowing that new drug development could bring significant financial gains. The court explicitly recognized that Kim pursued his own interests through this cooperation.
The investigation reports highlighted the possibility raised in the report that Kang may have exaggerated clinical results to deceive Kim. This serves as an important reference point for analyzing the bribery's background and motivation.
Investigation into Cause and Response
The Gensel founder's bribery case reflects a legal judgment regarding lobbying during new drug development. The court clearly acknowledged the quid pro quo nature and embezzlement/bribery acts, making it an important case highlighting ethical standards in the medical field.
The core of this case centered on the bribery path and its quid pro quo nature. Requesting clinical trial approval through Kim Seung-won at the Ministry of Food and Drug Safety was deemed clear lobbying, which the court classified as embezzlement. This case reiterates the importance of ethical standards and regulatory compliance in the medical industry.
As a result of the court ruling, Kang received a four-year prison sentence and is now in custody, demonstrating that illegal activities during new drug development will be strictly punished. Medical companies going forward will face stricter requirements for regulatory compliance and ethical operations.
Key Information to Verify: Major Aspects of the Case
Gensel founder Kang Se-chan was definitively sentenced to four years in prison on appeal on September 30, 2026, resulting in his custody. The core of the case involved allegations that he sought clinical trial approval through Kim Seung-won, which the court explicitly recognized as embezzlement/bribery.
While the first instance court had imposed a suspended sentence, this was overturned to a prison term on appeal. This change reflects evolving evidence and assessment of quid pro quo nature, with the court more clearly verifying specific circumstances related to the bribery.
Kim Seung-won was found to have cooperated with Kang despite knowing that new drug development could bring significant financial gains. Investigation reports also raised the possibility that Kang had exaggerated clinical results to deceive Kim, adding complexity to the case.
Frequently Asked Questions
What led to the conviction in the Gensel bribery case?
The court confirmed that Kang Se-chan sought new drug clinical trial approval through Kim Seung-won and clearly acknowledged the quid pro quo nature of the deal, as well as embezzlement/bribery acts. While a suspended sentence was initially imposed, the second instance court overturned this to impose a four-year prison term.
What role did Kim Seung-won play?
Kim Seung-won was found to have cooperated with Kang despite knowing that new drug development could bring significant financial gains. The court explicitly recognized that Kim pursued his own interests through this cooperation.
What does the investigation report say about Kang's alleged exaggeration of clinical results?
The investigation reports raised the possibility that Kang exaggerated clinical results to deceive Kim Seung-won. This serves as an important reference for analyzing the background and motivation behind the bribery, adding complexity to the case.
Frequently Asked Questions
Gensel founder Kang Se-chan was sentenced to four years in prison on appeal for allegedly seeking new drug clinical trial approval through Kim Seung-won. The court clearly acknowledged the quid pro quo nature and embezzlement/bribery acts, emphasizing the importance of ethical standards and regulatory compliance in the medical field.
This case demonstrates that illegal activities during new drug development will be strictly punished. Going forward, medical companies will face stricter requirements for regulatory compliance and ethical operations.
The case goes beyond a simple individual legal matter, raising the need for stronger regulation and ethical standards across the entire medical industry. The court's ruling is expected to serve as a strict benchmark for future similar cases.
You can view more articles on this topic in one place.
View Related ArticlesFAQ
What led to the conviction in the Gensel bribery case?
The court confirmed that Kang Se-chan sought new drug clinical trial approval through Kim Seung-won and clearly acknowledged the quid pro quo nature of the deal, as well as embezzlement/bribery acts. While a suspended sentence was initially imposed, the second instance court overturned this to impose a four-year prison term.
What role did Kim Seung-won play?
Kim Seung-won was found to have cooperated with Kang despite knowing that new drug development could bring significant financial gains. The court explicitly recognized that Kim pursued his own interests through this cooperation.
What does the investigation report say about Kang's alleged exaggeration of clinical results?
The investigation reports raised the possibility that Kang exaggerated clinical results to deceive Kim Seung-won. This serves as an important reference for analyzing the background and motivation behind the bribery, adding complexity to the case.
Korean Source
This article is an English localization of a Korean-language report from BlogScore. Original: 제넨셀 청탁 사건, 법원 판결 내용과 유죄 확정 과정